BMC 333
Alternative Names: BMC-333Latest Information Update: 02 May 2023
At a glance
- Originator Biomica
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 27 Apr 2023 Biomica plans a phase I trial for Inflammatory bowel diseases
- 13 Apr 2022 Biomica and Sheba Medical Center agree to co-develop therapeutic entities in Israel for inflammatory bowel disease
- 30 Nov 2021 Preclinical trials in Inflammatory bowel diseases in Israel (unspecified route), prior to November 2021